Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194712 | 0.88 | KCNH2 (0.47) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL30201993 | 0.86 | CCR1 (0.52) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL24916774 | 0.86 | CCR1 (0.52) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL10144469 | 0.84 | KCNH2 (0.54) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL1515200 | 0.82 | — | — | |
| SCHEMBL427622 | 0.80 | KCNH2 (0.52) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL1028715 | 0.78 | IRAK4 (0.47) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL1632272 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL12144269 | 0.78 | NOS2 (0.46) | SMN1; SMN2CCR1CCR8KDM1AMAOA | |
| SCHEMBL16565657 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2CCR1CCR8KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262183-B2 | Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases | Instititute of Pharmacology and Toxicology (CN) | 2007-08-28 | — | — | US | claimed |
| US-9126987-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-09-08 | — | — | US | disclosed |
| US-8288376-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| EP-2091948-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-8143248-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-1987010-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2091948-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| CN-101379041-A | Tricyclic N-heteroaryl-amide derivatives containing benzimidazole structural units, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-03-04 | — | — | CN | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| CN-1422851-A | Substituted five-membered nitrogen heterocyclic compound and application thereof in preventing and treating neurodegenerative diseases | TOXICANT AND MEDICINE INST MIL (CN) | 2003-06-11 | — | — | CN | disclosed |
| EP-1066307-A1 | 3',3'-N-BIS-SUBSTITUTED MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1066304-A1 | MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000012522-A1 | MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2000-03-09 | — | — | WO | disclosed |
| US-6020521-A | Macrolide LHRH antagonists | ABBOTT LABORATORIES (US) | 2000-02-01 | — | — | US | disclosed |
| US-5972898-A | ERYTHROMYCIN A DERIVATIVES AS LUTENIZING HORMONE RELEASING HORMONE (LHRH) ANTAGONISTS, AND METHODS OF THEIR PREPARATION | ABBOTT LABORATORIES (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999050275-A2 | MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050276-A1 | 3',3'-N-BIS-SUBSTITUTED MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5955440-A | 3'-N-DESMETHYL-3'-N-SUBSTITUTED-6-O-METHYL-11-DEOXY-11,12-CYCL IC CARBAMATE ERYTHROMYCIN A DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-09-21 | — | — | US | disclosed |
| CN-1209803-A | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method therefor | BRISTOL MYERS SQUIBB CO (US) | 1999-03-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, CYP3A43 | SMN1; SMN2 3560/4885CCR1 2776/4885CCR8 2922/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | SMN1; SMN2 3750/4885CCR1 2664/4885CCR8 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.